NCT02839707 2026-05-04Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerNational Cancer Institute (NCI)Phase 2/3 Active not recruiting444 enrolled 17 charts